JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: There is limited value in assessing the JAK2 V617F mutation in all newly presenting CML cases (McCarron et al., 2012[17]): screening for the less frequent CALR and MPL mutations in all likelihood would show a similar redundancy.